Studies (n=52) [6-57]
|
Continent (n=52)
|
North America
|
n=22
[10,11,14,18,19,22,26,27,29-38,40,41,43,59]
|
Europe
|
n=20 [9,13,15,20,21,23,24,28,39,44-47,49,52,53-55,57,58,]
|
South America
|
n=4 [16,17,48,56]
|
Australia
|
n=3 [42,50,60]
|
Asia
|
n=2 [12,25]
|
Africa
|
n=1 [51]
|
Study design (n=52)
|
Cohort
|
n=40 [9-21,23-27,29,31,32,34-36,38,41-48,50,51,53,55-57,60]
|
Randomized controlled trial
|
n=6 [28,30,33,37,40,54]
|
Cross-sectional
|
n=5 [22,39,49,58,59]
|
Non-randomized trial
|
n=1 [52]
|
Number of PICS-F areas areas by the studies (n=52)
|
1 outcome
|
n=27 [10,11,18,27,30-32,34,38,40-42,45,47-60]
|
> 1 outcomes
|
n=25 [9,12-17,19-26,28,29,33,35-37,39,43,44,46]
|
Patient population (n=45)
|
Σ=7448; R 17-1212; M=118; IQR 73-192 (no. of patients)
[9,10,12-24,27,28,30-32,34-38,40-50,52-54,56-60]
|
Age (n=40)
|
< 65 years
|
n=29 [9,10,14,15,17-19,27,28,30,32,34-40,45,47-50,52-54,56,58,60]
|
>= 65 years
|
n=11 [12,13,16,20,23,24,31,44,57,59]
|
Female sex (n=37)
|
R 19-63%; M=38%; IQR 33.5-44% [9,10,12-20,22,23,27,28,30-32,33,34-38,39,40,44,45,47-50,52,53,56-60]
|
Inclusion criteria (n=53)
|
ICU survival
|
n=14 [14,15,22,24,32,34-37,41,44,51,57,60]
|
ICU death
|
n=7 [12,28,33,39,46,55,59]
|
ICU stay/ MV > 24/48/72/more hrs
|
n=31 [9,16,17,19,21,22,25,26,28-30,31,34-38,40,42,44,45,47-54,56,58,60]
|
Others
|
n=10 [10,11,13,18,20,23,27,31,20,49]
|
ICU length of stay (n=26)
|
< 7 days
|
n=6 [9,17,18,48,49,60]
|
>= 7 days
|
n=21 [12,14,16,20,21,23,31-38,42,44,45,47,50,52,54,58]
|
Organ failure assessment (n=26)
|
SOFA (n=7)
|
R 1.5-14.73 pts; M=8.1 pts; IQR 2.4-14 pts
[12,15-17,20,23,30,48]
|
APACHE II (n=16)
|
R 15.2-56 pts; M=23.5 pts; IQR 19.9-31.3 pts
[12,14,18,21,22,32,35,36,42,44,47,49,50,53,54,60]
|
SAPS II (n=10)
|
R 29.6-64 pts; M=42.3 pts; IQR 39.7-61.2 pts
[15,17,19,42,49,50,52,55,56,58]
|
Overall mortality (n=36)
|
R 0-100%; M=21.5%; IQR 0-68.7% [12,14,15,16,18-20,22-24,28,30-37,39,41,42,44-47,49,51-57,59,60]
|
Population of relatives (n=52)
|
Σ=8293; R 28-1212; M=104; IQR 67-189 (no. of relatives) [9-60]
|
Age (n=46)
|
< 65 years
|
n=45 [9-21,23,25-30,32-45,47-49,51,53-56,58-60]
|
>= 65 years
|
n=1 [31]
|
Female sex (n=47)
|
R 25-84%; M=71%; IQR 64-74% [9-23,25-45,47-49,51,53-56,59,60]
|
Kinship
|
Spouses (n=45)
|
R 13-100%; M=48%; IQR 36.5-66% [9-16,18-45,47-50,52-56,58,60]
|
Children (n=38)
|
R 3-54%; M=26%; IQR 17.5-35.5% [9,10,12-15,18-23,25-31,33-45,47-50,52-56,58,60]
|
Parents (n=31)
|
R 2-27%; M=13%; IQR 9-18% [9,10,12-15,18,19,21-23,26,27,29-32,34-36,38-45,49.50,53-35,58,60]
|
Higher education (n=29)
|
R 14-91%; M=42%; IQR 34-73.5% [9-14,16,18,20,22,23,25-27,29,31,33,34,37,38,40,41,43,44,48,49,51,54,56,58]
|
Primary caregivers
|
100%
|
n=19 [10,11,21,22,27,29,30,34-38,41,44,48,50,56,57,60]
|
Unspecified/Other
|
n=26 [9,12-20,23-26,28,31-33,39,40,42,43,45-47,49,51-55,58,59]
|
Surrogate decision makers
|
100%
|
n=11 [12,13,19,23,40,42,43,46,49,53,59]
|
Anxiety studies (n=18)
|
R 3.3-69%; M=28%; IQR 15-39% [9,10,12-21,23-26]
|
Diagnostic tool (n=18)
|
HADS-A
|
n=17 [9-13,15-26]
|
GAD-7
|
n=1 [14]
|
Prevalence (n=16)
|
1 month (n=5)
|
R 10.7-34.2%; M=21%; IQR 15.1-28.07% [12,16,17,19,26]
|
3 months (n=9)
|
R 7.4-48%; M=32%; IQR 10.8-39.7% [10,12,13,16-18,20,23,24]
|
6 months (n=3)
|
R 3.3-32%; M=15% [10,12,26]
|
Other (n=6)
|
R 18-69%; M=39.5%; IQR 30.6-48% [9,14,15,19,21]
|
Loss-to-follow-up (n=23)
|
>20%
|
n=8 [9,10,12,16,19,24-26]
|
Depression studies (n=27)
|
R 5.3-56%; M=24%; IQR 19-34% [9,12-17,19-21,23,24,26-29,31-38]
|
Diagnostic tool (n=27)
|
HADS-D
|
n=15 [9,12,13,15-17,19-24,26-28]
|
PHQ
|
n=4 [14,29,30,33]
|
CES-D
|
n=7 [31,32,34-38]
|
BDI-13
|
n=1 [39]
|
Prevalence (n=23)
|
1 month (n=6)
|
R 5.8-49.3%; M=20.3%; IQR 8-42% [12,16,17,19,26,28]
|
2 months (n=7)
|
R 5.25-56%; M=33.93%; IQR 31.1-43.3% [19,32,34-38]
|
3 months (n=9)
|
R 5.3-39%; M=20%; IQR 15.9-29% [12,13,16,17,20,23,24,27,29]
|
6 months (n=7)
|
R 6-30.8%; M=19.2%; IQR 14.9-30% [12,26-28,33,35,36]
|
12 months (n=2)
|
R 22.8-29.2% [35,36]
|
Other (n=4)
|
R 21-55%; M=28.2.%; IQR 21.7-44.5% [9,14,21,31]
|
Loss-to-follow-up (n=26)
|
>20%
|
n=11 [9,12,16,19,24,26,27,30,32,34,37]
|
PTSD studies (n=31)
|
R 2.5-67.6%; M=31%; IQR 17-45% [9,14,15,19-21,23-26,28,29,34,40-54]
|
Diagnostic tool (n=31)
|
IES/IES-R
|
n=21 [9,15,17,20,23-29,39,40,42,43,46,48-54]
|
PCL-C/S/5
|
n=6 [14,19,34,41,47,51]
|
Other (n)
|
n=4 [19,22,44,45]
|
Prevalence (n=28)
|
1 month (n=3)
|
R 2.5-7.9%; M=7.7% [19,43,48]
|
2 months (n=3)
|
R 11.1-35%; M=22.9% [19,25,47]
|
3 months (n=10)
|
R 15-51%; M=29.9%; IQR 18-39% [20,23,24,29,40-42,44,50,53]
|
6 months (n=8)
|
R 14-57.1%; M=39.3%; IQR 19.5-46.9% [26,28,34,41,43,46,51,54]
|
Other (n=7)
|
R 15.7-67.6%; M=45%; IQR 31-59.1% [9,14,15,21,45,49,52]
|
Loss-to-follow-up (n=29)
|
>20%
|
n=8 [9,19,25,26,41,43,46,48]
|
Complicated grief studies (n=5)
|
R 21.7-52.1%; M=46%; IQR 27-49.9% [26,28,44,47,55]
|
Diagnostic tool (n=5)
|
ICG/ICG-R
|
n=5 [26,28,44,47,55]
|
Prevalence (n=5)
|
6 months (n=4)
|
R 21.7--52.1%; M=39.2%; IQR 27-49% [26,28,44,47]
|
9 months (n=1)
|
47.7% [55]
|
Loss-to-follow-up (n=5)
|
>20%
|
n=3 [44,47,26]
|
Caregiver burden/strain studies (n=6)
|
R 21-72.4%; M=45%; IQR 29-62.7% [21,37,45,56,57,60]
|
Diagnostic tool (n=6)
|
ZBI
|
n=2 [56,57]
|
CSI
|
n=2 [21,45]
|
Other
|
n=2 [37,60]
|
Prevalence (n=4)
|
Various time points
|
R 21-72.4%; M=45%; IQR 29-62.7% [21,45,46,57]
|
Loss-to-follow-up (n=5)
|
>20%
|
n=3 [37,45,58]
|
Other PICS-F areas (n=4)
|
Look at chapter: Post-intensive care syndrome in families
|